GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...

The awards are presented annually to organizations in the Greater Philadelphia and Triangle (North Carolina) regions.

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

The weaker backdrop means the FTSE 100 index is forecast to give up all yesterday’s rise, with futures pointing to a decline ...

Nina Mojas, senior vice president, oncology global product strategy, GSK, said: “At GSK, we continue to develop new therapies for patients with gynaecologic cancers, yet we know there are also ...

Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib ... This approval is based on the results ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...